Low plasma levels of dehydroepiandrosterone (DHEA) and incidence of lipodystrophy

HIV Medicine

Volumn 2, Issue 2, 2001, Pages 136-138

  Piketty, C ^a,d   Jayle, D ^a   Gonzalez Canali, G ^a   Debuire, B ^b   Baulieu, E E ^c   Kazatchkine, M D ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c BICÊTRE HOSPITAL   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; NELFINAVIR; PRASTERONE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYMATIC ASSAY; HELPER CELL; HORMONE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIPODYSTROPHY; LYMPHOCYTE COUNT; PRIORITY JOURNAL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL AVAILABILITY; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; LIPODYSTROPHY; MALE; RISK FACTORS; SAFETY; TREATMENT OUTCOME;

EID: 0035198876     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2001.002002136.x     Document Type: Article

References (20)

1. Dehydroepiandrosterone (DHEA): A fountain of youth?
2. Dehydroepiandrosterone and androsterone levels in human plasma. Effect of age and sex, day-to-day and diurnal variations
3. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men
4. Plasma dehydroepiandrosterone levels in HIV infection
5. Decreases serum dehydroepiandrosterone is associated with increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200-499
6. Dehydroepiandrosterone as a predictor for progression in AIDS in asymptomatic human immunodeficiency virus-infected men
7. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue
8. Dehydroepiandrosterone replacement administration: Pharmacokinetic and pharmacodynamic studies in healthy elderly subjects
9. An open-label dose-escalading trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease
10. Double blind placebo-controlled trial of oral dehydroepiandrosterone (DHEA) in patients with advanced HIV disease
11. Fat distribution and metabolic changes in patients with HIV infection
12. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
13. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
14. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
15. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
16. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART)
17. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
18. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidaemia and steroid hormone alterations
19. Syndrome of body fat redistribution in HIV-1-infected patients: Relationships to cortisol and catecholamines
20. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: A French community-based study